Pros | - | ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 6 Years | ||
Fund Size | 214 Cr | 83 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹200 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 1.22% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 29 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.22%) Divi's Laboratories Ltd (5.96%) Lupin Ltd (5.78%) Suven Pharmaceuticals Ltd (5.39%) Apollo Hospitals Enterprise Ltd (5.16%) | Sun Pharmaceuticals Industries Ltd (10.03%) Piramal Pharma Ltd (5.9%) Torrent Pharmaceuticals Ltd (5.29%) Artemis Medicare Services Ltd Ordinary Shares (5.09%) Glenmark Pharmaceuticals Ltd (4.59%) | ||
No of Sectors | 3 | 2 | ||
Top 3 Sectors | Health (95.43%) Basic Materials (3.54%) Industrial (1.03%) | Health (93.32%) Basic Materials (6.68%) | ||
Equity % | 97.95% | 98.03% | ||
Debt % | - | - | ||
P/E | 37.64 | 40.52 | ||
P/B | 5.87 | 5.88 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 5.53% | 5.28% | ||
3-Month Return | -3.65% | -2.63% | ||
6-Month Return | -7.87% | -7.54% | ||
1-Year Return | 17.52% | 19.31% | ||
3-Year Return | 19.69% | 16.73% | ||
5-Year Return | - | 19.38% |
Sharpe | 0.84 | 0.69 | ||
Alpha | 2.89 | -1.35 | ||
Beta | 0.91 | 0.93 | ||
Standard Deviation | 16.41 | 16.51 | ||
Information Ratio | 0.51 | -0.63 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | LIC MF Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Karan Doshi |